Try our mobile app
Screener

Reviews

2026-02-26
#reports #ZVIA

[Zevia PBC](https://eninvs.com/all.php?name=ZVIA) (Beverages — Non-Alcoholic) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195122)
(2026-02-25, After Market Close):

- Revenue -2.6% YoY (vs +13.9% in previous quarter and historical rate +0.4%)
- EBITDA margin -2.6% increased compared to -15.4% same period last year
- Net Debt increased by $1 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) -$0 bln (negative), 7.4% of market cap
- EV/Sales multiple is 0.6x

2026-02-26
#reports #XPER

[Xperi](https://eninvs.com/all.php?name=XPER) (Semiconductor Equipment and Materials) reported for 2025 q4
(2026-02-25, After Market Close):

- Revenue -4.1% YoY (vs -15.8% in previous quarter and historical rate -15.8%)
- EBITDA margin -8.5% increased compared to -9.0% same period last year
- Net Debt decreased by $2 mln over the past reporting period (0.8% of market cap)
- FCF (LTM) +$0 bln (positive), 2.8% of market cap
- EV/Sales multiple is 0.5x

2026-02-26
#reports #XPEL

[XPEL](https://eninvs.com/all.php?name=XPEL) (Automotive surface protection products manufacturer) reported for 2025 q4
(2026-02-25, Before Market Open):

- Revenue +13% YoY (vs +10.6% in previous quarter and historical rate +14.0%)
- EBITDA +21.4% YoY (vs -10.0% in previous quarter and historical rate +7.1%)
- EBITDA margin 13.9% increased compared to 13.0% same period last year
- Net Debt increased by $20 mln over the past reporting period (1.4% of market cap)
- FCF (LTM) +$0 bln (positive), 1.0% of market cap
- EV/EBITDA multiple is 21.1x compared to historical level (75th percentile) of 21.9x
- EV/Sales multiple is 3.1x

2026-02-26
#reports #VECO

[Veeco Instruments](https://eninvs.com/all.php?name=VECO) (Semiconductor Equipment and Materials) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195118)
(2026-02-25, After Market Close):

- Revenue -9.3% YoY (vs -10.3% in previous quarter and historical rate +1.2%)
- EBITDA -50% YoY (vs -54.5% in previous quarter and historical rate -10.1%)
- EBITDA margin 2.4% decreased compared to 4.4% same period last year
- Net Debt decreased by $21 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) +$0.1 bln (positive), 4.1% of market cap
- EV/EBITDA multiple is 31.6x compared to historical level (75th percentile) of 20.4x
- EV/Sales multiple is 2.6x

2026-02-26
#reports #VCYT

[Veracyte](https://eninvs.com/all.php?name=VCYT) (Medical services provider) reported for 2025 q4
(2026-02-25, After Market Close):

- Revenue +18.5% YoY (vs +13.8% in previous quarter and historical rate +20.3%)
- EBITDA +320% YoY (vs +55.6% in previous quarter)
- EBITDA margin 29.8% increased compared to 8.4% same period last year
- Net Debt decreased by $47 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) +$0.1 bln (positive), 2.7% of market cap
- EV/EBITDA multiple is 38.9x compared to historical level (75th percentile) of 74.5x
- EV/Sales multiple is 5.5x

2026-02-26
#reports #UHS

[Universal Health Services](https://eninvs.com/all.php?name=UHS) (Medical services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195116)
(2026-02-25, After Market Close):

- Revenue -19.3% YoY (vs +13.4% in previous quarter and historical rate +31.1%)
- EBITDA +4.2% YoY (vs +26.8% in previous quarter and historical rate +19.3%)
- EBITDA margin 11.6% increased compared to 9.0% same period last year
- Net Debt increased by $36 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) -$0.2 bln (negative), 1.3% of market cap
- EV/EBITDA multiple is 7.7x compared to historical level (75th percentile) of 10.4x
- EV/Sales multiple is 1.2x

2026-02-26
#reports #TPH

[Tri Pointe Homes](https://eninvs.com/all.php?name=TPH) (House builder ) reported for 2025 q4
(2026-02-25, Before Market Open):

- Revenue -22.4% YoY (vs -25.7% in previous quarter and historical rate -4.3%)
- EBITDA -48.3% YoY (vs -53.2% in previous quarter and historical rate -7.3%)
- EBITDA margin 9.4% decreased compared to 14.1% same period last year
- Net Debt decreased by $381 mln over the past reporting period (13.2% of market cap)
- FCF (LTM) -$0.4 bln (negative), 12.4% of market cap
- EV/EBITDA multiple is 4.9x compared to historical level (75th percentile) of 5.7x
- EV/Sales multiple is 0.5x

2026-02-26
#reports #TDOC

[Teladoc Health](https://eninvs.com/all.php?name=TDOC) (Health care provider) reported for 2025 q4
(2026-02-25, After Market Close):

- Revenue +0.3% YoY (vs -2.3% in previous quarter and historical rate +1.8%)
- EBITDA margin -5.1% increased compared to -6.7% same period last year
- Net Debt decreased by $58 mln over the past reporting period (10.2% of market cap)
- FCF (LTM) -$0 bln (negative), 5.3% of market cap
- EV/Sales multiple is 0.3x

2026-02-26
#reports #SRPT

[Sarepta Therapeutics](https://eninvs.com/all.php?name=SRPT) (Therapeutic developer) reported for 2025 q4
(2026-02-25, After Market Close):

- Revenue +11.6% YoY (vs +40.7% in previous quarter and historical rate +35.0%)
- EBITDA margin -92.8% decreased compared to -7.1% same period last year
- Net Debt decreased by $1.3 bln since the start of the year (54.9% of market cap)
- FCF (LTM) -$0.2 bln (negative), 9.7% of market cap
- EV/Sales multiple is 1.4x

2026-02-26
#reports #SNPS

[Synopsys](https://eninvs.com/all.php?name=SNPS) (Electronics design technology provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195112)
(2026-02-25, After Market Close):

- Revenue +57.9% YoY (vs +55.0% in previous quarter and historical rate +16.2%)
- EBITDA -37.2% YoY (vs -18.4% in previous quarter and historical rate +4.0%)
- EBITDA margin 11.4% decreased compared to 28.6% same period last year
- Net Debt decreased by $12.7 bln since the start of the year (16.4% of market cap)
- EV/EBITDA multiple is 60.8x compared to historical level (75th percentile) of 51.9x
- EV/Sales multiple is 10x

2026-02-26
#reports #SHOO

[Steven Madden](https://eninvs.com/all.php?name=SHOO) (Women`s shoes manufacturer) reported for 2025 q4
(2026-02-25, Before Market Open):

- Revenue +36.6% YoY (vs +11.9% in previous quarter and historical rate +7.9%)
- EBITDA -18% YoY (vs +18.2% in previous quarter and historical rate -8.8%)
- EBITDA margin 6.6% decreased compared to 11.1% same period last year
- Net Debt increased by $420 mln over the past reporting period (13.0% of market cap)
- FCF (LTM) +$0 bln (positive), 1.2% of market cap
- EV/EBITDA multiple is 15.5x compared to historical level (75th percentile) of 13x
- EV/Sales multiple is 1.5x

2026-02-26
#reports #SDGR

[Schrodinger/United States](https://eninvs.com/all.php?name=SDGR) (Software developer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195111)
(2026-02-25, After Market Close):

- Revenue +62.2% YoY (vs +54.3% in previous quarter and historical rate +22.4%)
- EBITDA margin -76.7% increased compared to -178.4% same period last year
- Net Debt decreased by $6 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) +$0 bln (positive), 4.2% of market cap
- EV/Sales multiple is 3.6x

2026-02-26
#reports #RXST

[RxSight, Inc.](https://eninvs.com/all.php?name=RXST) (Medical Devices) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195110)
(2026-02-25, After Market Close):

- Revenue -17.5% YoY (vs -14.3% in previous quarter and historical rate +46.9%)
- EBITDA margin -30.3% decreased compared to -20.0% same period last year
- Net Debt decreased by $1 mln over the past reporting period (0.4% of market cap)
- FCF (LTM) -$0 bln (negative), 3.4% of market cap
- EV/Sales multiple is 0.3x

2026-02-26
#reports #RXRX

[Recursion Pharmaceuticals, Inc.](https://eninvs.com/all.php?name=RXRX) (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195109)
(2026-02-25, Before Market Open):

- Revenue +227.3% YoY (vs +136.4% in previous quarter and historical rate +96.2%)
- EBITDA margin -300.0% increased compared to -881.8% same period last year
- Net Debt decreased by $716 mln over the past reporting period (29.6% of market cap)
- FCF (LTM) -$0.4 bln (negative), 16.2% of market cap
- EV/Sales multiple is 19.5x

2026-02-26
#reports #RRGB

[Red Robin Gourmet Burgers](https://eninvs.com/all.php?name=RRGB) (Restaurant chain owner) reported for 2025 q4
(2026-02-25, After Market Close):

- Revenue -5.6% YoY (vs -3.6% in previous quarter and historical rate -1.5%)
- EBITDA margin 3.0% increased compared to -7.4% same period last year
- Net Debt decreased by $11 mln over the past reporting period (15.6% of market cap)
- FCF (LTM) +$0 bln (positive), 59.8% of market cap
- EV/EBITDA multiple is 13.8x compared to historical level (75th percentile) of 55.5x
- EV/Sales multiple is 0.5x

2026-02-26
#reports #ROOT

[Root, Inc.](https://eninvs.com/all.php?name=ROOT) (Insurance — Property and Casualty) reported for 2025 q4
(2026-02-25, After Market Close):

- Revenue +55.7% YoY (vs +67.7% in previous quarter and historical rate +70.0%)
- Net Income margin 1.3% increased compared to -2.4% same period last year
- P/E multiple is 23.3x compared to historical level (75th percentile) of 58.9x
- P/S multiple is 0.7x
- Price to book: 3.7x

2026-02-26
#reports #PRCT

[PROCEPT BioRobotics Corporation](https://eninvs.com/all.php?name=PRCT) (Medical Devices) reported for 2025 q4
(2026-02-24, After Market Close):

- Revenue +11.8% YoY (vs +43.1% in previous quarter and historical rate +62.5%)
- EBITDA margin -72.4% decreased compared to -64.7% same period last year
- Net Debt increased by $7 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0 bln (negative), 2.7% of market cap
- EV/Sales multiple is 3.6x

2026-02-26
#reports #PLAB

[Photronics](https://eninvs.com/all.php?name=PLAB) (Semiconductor Equipment and Materials) reported for 2025 q4
(2026-02-25, Before Market Open):

- Revenue +6.1% YoY (vs -75.1% in previous quarter and historical rate +11.6%)
- EBITDA +2.7% YoY (vs -82.9% in previous quarter and historical rate +7.8%)
- EBITDA margin 33.3% decreased compared to 34.4% same period last year
- Net Debt increased by $294 mln over the past reporting period (14.7% of market cap)
- FCF (LTM) -$0 bln (negative), 0.9% of market cap
- EV/EBITDA multiple is 7.7x compared to historical level (75th percentile) of 4.7x
- EV/Sales multiple is 2.1x

2026-02-26
#reports #PEN

[Penumbra](https://eninvs.com/all.php?name=PEN) (Medical equipment manufacturer) reported for 2025 q4
(2026-02-24, After Market Close):

- Revenue +21.8% YoY (vs +17.9% in previous quarter and historical rate +18.4%)
- EBITDA +33.3% YoY (vs +38.2% in previous quarter and historical rate +100.9%)
- EBITDA margin 16.6% increased compared to 15.2% same period last year
- Net Debt increased by $137 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) +$0 bln (positive), 0.0% of market cap
- EV/EBITDA multiple is 68.8x compared to historical level (75th percentile) of 395.1x
- EV/Sales multiple is 10.1x

2026-02-26
#reports #PEB

[Pebblebrook Hotel Trust](https://eninvs.com/all.php?name=PEB) (REIT — Hotel and Motel) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195103)
(2026-02-25, After Market Close):

- Revenue +3.3% YoY (vs -1.5% in previous quarter and historical rate -0.9%)
- EBITDA +82.9% YoY (vs -55.2% in previous quarter and historical rate +5.7%)
- EBITDA margin 18.3% increased compared to 10.4% same period last year
- Net Debt increased by $19 mln over the past reporting period (1.2% of market cap)
- FCF (LTM) +$0 bln (positive), 0.7% of market cap
- EV/EBITDA multiple is 14.1x compared to historical level (75th percentile) of 15.5x
- EV/Sales multiple is 2.6x

2026-02-26
#reports #OC

[Owens Corning](https://eninvs.com/all.php?name=OC) (Building products manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195102)
(2026-02-25, Before Market Open):

- Revenue -79% YoY (vs -11.9% in previous quarter and historical rate +12.1%)
- EBITDA -42.6% YoY (vs -114.6% in previous quarter and historical rate +1.0%)
- EBITDA margin 27.8% increased compared to 10.2% same period last year
- Net Debt increased by $39 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) -$0.1 bln (negative), 0.5% of market cap
- EV/EBITDA multiple is 9.9x compared to historical level (75th percentile) of 7.9x
- EV/Sales multiple is 1.7x